China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
Following GSK's landmark $500 million licensing deal with Jiangsu Hengrui, we're seeing a strategic shift where global pharmaceutical giants are turning to Chinese innovators to enhance their drug pipelines. This signals growing recognition of China's biopharmaceutical sector as a critical source of novel drug innovation and creates opportunities for similar lucrative partnerships.
What You Need to Know
These Chinese biopharma companies focus on developing promising drug candidates through early-stage trials before seeking larger partners for late-stage development and global commercialization. The investment appeal lies in potential value uplift from upfront payments, milestone achievements, and future royalties from partnership agreements.
Why These Stocks
This group was carefully curated to include innovative Chinese biopharma companies with advanced research and development capabilities that are creating valuable intellectual property. These firms are well-positioned to secure their own lucrative licensing and partnership agreements as global pharma companies increasingly seek external innovation.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+332.87%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 332.87% over the next year.
Stocks Rated Buy by Analysts
15 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Partnership Gold Rush
Following GSK's $500 million deal with Jiangsu Hengrui, global pharmaceutical giants are actively seeking Chinese innovation partners. These companies could be next in line for similar lucrative agreements.
Innovation Pipeline Power
China's biopharma sector is rapidly advancing with novel drug candidates that global companies desperately need to fill their pipelines. The potential for breakthrough discoveries is creating massive value opportunities.
Multi-Million Dollar Upside
Partnership deals in this sector often involve substantial upfront payments, milestone bonuses, and ongoing royalties. A single licensing agreement can transform a company's valuation overnight.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.